Last C$0.05 CAD
Change Today +0.005 / 11.11%
Volume 27.9K
ICO On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 10:57 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

ico therapeutics inc (ICO) Snapshot

Open
C$0.05
Previous Close
C$0.05
Day High
C$0.05
Day Low
C$0.05
52 Week High
03/6/14 - C$0.59
52 Week Low
09/25/14 - C$0.05
Market Cap
4.2M
Average Volume 10 Days
203.9K
EPS TTM
C$-0.09
Shares Outstanding
84.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ICO THERAPEUTICS INC (ICO)

Related News

No related news articles were found.

ico therapeutics inc (ICO) Related Businessweek News

View More BusinessWeek News

ico therapeutics inc (ICO) Details

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-007, an antisense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; and iCo-008 (Bertilimumab), a human immunoglobulin monoclonal antibody, which is in Phase I clinical trial to treat sight threatening ocular allergies and various systemic indications. The company also develops Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

5 Employees
Last Reported Date: 04/24/14
Founded in 2005

ico therapeutics inc (ICO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$234.7K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$140.0K
Chief Medical Officer
Total Annual Compensation: C$160.0K
Compensation as of Fiscal Year 2013.

ico therapeutics inc (ICO) Key Developments

iCo Therapeutics Inc. Announces Earnings Results for the Six Months Ended June 30, 2014

iCo Therapeutics Inc. announced earnings results for the six months ended June 30, 2014. The company incurred total comprehensive loss of CAD 1,617,040 or loss per share of CAD 0.02 for the six months ended June 30, 2014 compared to a total comprehensive loss of CAD 2,886,831 or loss per share of CAD 0.05 for the six months ended June 30, 2013, representing a decrease of CAD 1,269,791 in comprehensive loss. The decrease in net comprehensive loss is primarily a result of a CAD 259,755 increase in the carrying value of its investment in Immune Pharmaceuticals, as well as a decrease in expenses associated with the iDEAL trial.

iCo Therapeutics Inc. Announces Positive Oral Amphotericin B Study Results

iCo Therapeutics Inc. reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta(R), the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy. Memory cells, or white blood cells, from eight HIV-infected subjects with a durable viral suppression using antiretroviral therapy (HAART) were obtained and exposed in vitro to various concentrations of Oral Amp B. Samples from one patient were determined not to be susceptible to reactivation. In the remaining subjects, Oral Amp B demonstrated a reactivation response of HIV viral production in six out of seven in vitro cultures with detectable HIV reservoir. Some HIV reservoirs are not possible to reactivate and this may explain why one culture did not show reactivation response.

iCo Therapeutics Inc. Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 Ideal Study in Diabetic Macular Edema

iCo Therapeutics Inc. announced top-line results related to the eight month visual acuity (VA) primary endpoint for subjects enrolled in the Phase 2 iDEAL Study, conducted in collaboration with JDRF, evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). Statistical methods employed included both Last Observation Carry Forward (LOCF) and Multiple Imputation (MI) analyses given the departure of patients from the study prior to their eight month visit. Using both statistical methods, mean changes in visual acuity measures in all four groups at both month four and month eight were negative. Using the LOCF method, mean change in VA at eight months was approximately minus 11 letters (350 ug monotherapy), minus 21 letters (700 ug monotherapy), minus 14 letters (350 ug + laser arm) and minus 14 letters (350 ug + Lucentis). Some patients in each cohort did show improvements in mean change in VA. At eight months using the LOCF analysis, roughly 20% of patients in the 350 ug monotherapy arm gained five letters or greater of vision versus 13% in the 700 ug monotherapy arm, 12% in the 350 ug + laser arm and 11% in the 350 ug + Lucentis arm. At four months, patients gaining five letters or more for the 350 ug, 700 ug, 350 ug + laser and 350 ug + Lucentis arms were approximately 24%, 18%, 21% and 30%, respectively. Using the LOCF method it was observed that at month eight there was an inverse statistically significant difference in mean VA change from baseline between 350 ug monotherapy and 700 ug monotherapy arms, meaning there was greater loss of VA in the 700 ug monotherapy cohort. There was no statistically significant difference in mean VA between the 350 ug monotherapy and either 350 ug + laser or 350 ug + Lucentis arms. When using MI analysis there was no statistically significant difference observed between 350 ug monotherapy and each of the 700 ug monotherapy, 350 ug + laser and 350 ug + Lucentis arms. At eight months, in the 700 ug monotherapy arm, 64% of patients experienced a 15 letter or greater loss of vision, compared to 33% in the 350 ug monotherapy arm, 33% in the 350 ug + laser arm, and 41% in the 350 ug + Lucentis arm. At four months the corresponding numbers were 29%, 9%, 9%, and 14%, respectively.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICO:CN C$0.05 CAD +0.005

ICO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICO.
View Industry Companies
 

Industry Analysis

ICO

Industry Average

Valuation ICO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICO THERAPEUTICS INC, please visit www.icotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.